Pfizer Wins FDA Approval for Pneumococcal 20-Valent Conjugate Vaccine

The FDA has approved Pfizer’s Prevnar 20 conjugate vaccine, which prevents invasive disease and pneumonia from 20 different strains of streptococcus.

The pneumococcal 20-valent conjugate vaccine, which was indicated for adults 18 years and older, includes seven strains responsible for 40 percent of U.S. pneumococcal disease cases and deaths, Pfizer said.

The approval was supported by multiple trials, including three phase 3 studies that enrolled more than 6,000 adult patients, including individuals over 65 years old, those who had received previous pneumococcal vaccinations and those who had not ever received the shots.